Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients
NCT ID: NCT05346419
Last Updated: 2022-04-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
33 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-01
Study Completion Date
2022-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopause. Recently, a high prevalence of hypovitaminosis D has been found worldwide, which could trigger a state of secondary hyperparathyroidism that can worsen the state of postmenopausal patients with osteoporosis. An open-label, clinical trial was conducted in Mexican women with postmenopausal osteopenia-osteoporosis to determine the efficacy of the combined treatment with risedronate and high-dose vitamin D in improving bone mineral density, hyperparathyroidism, and hypovitaminosis D.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
NCT05347082
Postmenopausal Osteoporosis
Postmenopause
Hyperparathyroidism, Secondary
+2 more
COMPLETED
NA
Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
NCT05372224
Hypovitaminosis D
Osteoporosis, Postmenopausal
Menopause
COMPLETED
NA
Post-menopausal Women Osteoporosis(Phase III)
NCT01806792
Postmenopausal Women Osteoporosis
COMPLETED
PHASE3
Risedronate in Postmenopausal Women With Low Bone Density
NCT00351091
OSTEOPOROSIS, POSTMENOPAUSAL
COMPLETED
PHASE2
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00402441
Osteoporosis, Postmenopausal
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants were selected from the climacteric clinic of the regional hospital "1ro de Octubre-Instituto de Seguridad y Servicios Sociales para Los Trabajadores del Estado (ISSSTE)", Mexico. All participants voluntarily accepted to be part of the study and provided written informed consent.This study was approved by the institutional ethical committee of the hospital with registration number COFEPRIS 17 CI 09005135 with the internal registration number 118.2021. Every participant was clinically examined. Their metabolic state was assessed by considering height, weight, body mass index (BMI) and the percentage of Hb1Ac.
33 patients were included among 40 to 78 years with the diagnosis of postmenopausal osteoporosis with associated hyperparathyroidism, hypovitaminosis D or both conditions. All the patients were treated for 6 months with 35 mg of risedronate and 2800 IU of vitamin D once a week, with additional daily supplementation of 4000 IU of vitamin D.
Statical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. Some statical parameters, such as arithmetic median (µ), and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables were done in Excel-Word. The assigned α value for this study was \<0.05.
33 patients were included among 40 to 78 years with the diagnosis of postmenopausal osteoporosis with associated hyperparathyroidism, hypovitaminosis D or both conditions. All the patients were treated for 6 months with 35 mg of risedronate and 2800 IU of vitamin D once a week, with additional daily supplementation of 4000 IU of vitamin D.
Statical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. Some statical parameters, such as arithmetic median (µ), and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables were done in Excel-Word. The assigned α value for this study was \<0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Postmenopausal Osteoporosis
Hypovitaminosis D
Hyperparathyroidism
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
33 participants between 40 and 78 years old with a diagnosis of postmenopausal osteoporosis or osteopenia with associated hyperparathyroidism, hypovitaminosis or both conditions were selected. All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Postmenopausal Osteopenia-osteoporosis patients
All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
Group Type
EXPERIMENTAL
Risedronate
Intervention Type
DRUG
Participants received risedronate 35 mg once a week for 6 months.
Vitamin D
Intervention Type
DRUG
Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risedronate
Participants received risedronate 35 mg once a week for 6 months.
Intervention Type
DRUG
Vitamin D
Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
SERALIS®
Generic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with a diagnosis of postmenopausal osteoporosis or osteopenia.
* Participants with a diagnosis of hyperparathyroidism or hypovitaminosis D.
* Participants who accepted to participate and that provided informed consent.
* Participants with a diagnosis of hyperparathyroidism or hypovitaminosis D.
* Participants who accepted to participate and that provided informed consent.
Exclusion Criteria
* Participants with oncological pathologies.
* Participants with recent fractures.
* Participants with gastric intolerance or hypersensitivity to the drugs.
* Participants were under treatment with another antiresorptive or bone-forming drug, or if they were receiving treatment with thiazide diuretics, lithium, teriparatide or glucocorticoids.
* Participants with Addison's disease, pheochromocytoma or depressive disorders.
* Participants with recent fractures.
* Participants with gastric intolerance or hypersensitivity to the drugs.
* Participants were under treatment with another antiresorptive or bone-forming drug, or if they were receiving treatment with thiazide diuretics, lithium, teriparatide or glucocorticoids.
* Participants with Addison's disease, pheochromocytoma or depressive disorders.
Minimum Eligible Age
40 Years
Maximum Eligible Age
78 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Polytechnic Institute, Mexico
OTHER
Sponsor Role
collaborator
Universidad Nacional Autonoma de Mexico
OTHER
Sponsor Role
collaborator
Hospital Regional 1o de Octubre
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan M Ocampo Godínez, M.D., Ph.D.
Role: STUDY_DIRECTOR
Tissue Bioengineering Laboratory, National Autonomous University of Mexico [UNAM]
Patricia Loranca-Moreno, M.D., M.Sc.
Role: STUDY_DIRECTOR
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE.
Merle Y Hernández-Castañón, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE
Mexico City, , Mexico
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Mexico
References
Explore related publications, articles, or registry entries linked to this study.
Cossio-Bolanos M, Vidal-Espinoza R, Fuentes-Lopez J, Castelli Correia de Campos LF, Andruske CL, Urra-Albornoz C, Alvear Vasquez F, Gomez-Campos R. Reference values for bone density and bone mineral content from 5 to 80 years old in a province of Chile. PeerJ. 2022 Mar 23;10:e13092. doi: 10.7717/peerj.13092. eCollection 2022.
Reference Type
BACKGROUND
Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018-4704-5. Epub 2018 Oct 15.
Reference Type
BACKGROUND
Deng W, Han JC, Chen L, Qi WL. Estrogen receptor alpha gene PvuII polymorphism and risk of fracture in postmenopausal women: a meta-analysis. Genet Mol Res. 2015 Feb 13;14(1):1293-300. doi: 10.4238/2015.February.13.8.
Reference Type
BACKGROUND
Aziziyeh R, Amin M, Habib M, Perlaza JG, McTavish RK, Ludke A, Fernandes S, Sripada K, Cameron C. A scorecard for osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. Arch Osteoporos. 2019 Jun 27;14(1):69. doi: 10.1007/s11657-019-0622-1.
Reference Type
BACKGROUND
Moschonis G, van den Heuvel EG, Mavrogianni C, Manios Y. Effect of Vitamin D-Enriched Gouda-Type Cheese Consumption on Biochemical Markers of Bone Metabolism in Postmenopausal Women in Greece. Nutrients. 2021 Aug 27;13(9):2985. doi: 10.3390/nu13092985.
Reference Type
BACKGROUND
Bouloukaki I, Markakis M, Pateli R, Lyronis I, Schiza S, Tsiligianni I. Vitamin D levels in primary care patients: correlations with clinical, seasonal, and quality-of-life parameters. Fam Pract. 2022 Jul 19;39(4):678-684. doi: 10.1093/fampra/cmac012.
Reference Type
BACKGROUND
Dixit V, Tripathi RL, Dhanwal DK. Lack of secondary hyperparathyroidism in sub-group of vitamin D deficient postmenopausal women: Is VDR gene polymorphism behind this mystery? Diabetes Metab Syndr. 2022 Jan;16(1):102381. doi: 10.1016/j.dsx.2021.102381. Epub 2021 Dec 28.
Reference Type
BACKGROUND
Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G, Ragi-Eis S, Chandler J. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006 Sep;260(3):245-54. doi: 10.1111/j.1365-2796.2006.01685.x.
Reference Type
BACKGROUND
Martinez-Zavala N, Lopez-Sanchez GN, Vergara-Lopez A, Chavez-Tapia NC, Uribe M, Nuno-Lambarri N. Vitamin D deficiency in Mexicans have a high prevalence: a cross-sectional analysis of the patients from the Centro Medico Nacional 20 de Noviembre. Arch Osteoporos. 2020 Jun 16;15(1):88. doi: 10.1007/s11657-020-00765-w.
Reference Type
BACKGROUND
Wihlborg A, Bergstrom K, Gerdhem P, Bergstrom I. Parathyroid Hormone Disturbances in Postmenopausal Women with Distal Forearm Fracture. World J Surg. 2022 Jan;46(1):128-135. doi: 10.1007/s00268-021-06331-w. Epub 2021 Oct 13.
Reference Type
BACKGROUND
Yalla N, Bobba G, Guo G, Stankiewicz A, Ostlund R. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest. 2019 Nov;42(11):1353-1360. doi: 10.1007/s40618-019-01075-w. Epub 2019 Jul 4.
Reference Type
BACKGROUND
Clark P, Vivanco-Munoz N, Pina JT, Rivas-Ruiz R, Huitron G, Chico-Barba G, Reza-Albarran AA. High prevalence of hypovitaminosis D in Mexicans aged 14 years and older and its correlation with parathyroid hormone. Arch Osteoporos. 2015;10:225. doi: 10.1007/s11657-015-0225-4. Epub 2015 Jul 14.
Reference Type
BACKGROUND
Yuan F, Peng W, Yang C, Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019 Jun;66:1-11. doi: 10.1016/j.ijsu.2019.03.004. Epub 2019 Mar 16.
Reference Type
BACKGROUND
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
Reference Type
BACKGROUND
Soreskog E, Lindberg I, Kanis JA, Akesson KE, Willems D, Lorentzon M, Strom O, Berling P, Borgstrom F. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int. 2021 Mar;32(3):585-594. doi: 10.1007/s00198-020-05780-8. Epub 2021 Jan 6.
Reference Type
BACKGROUND
Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Atsumi T, Miyoshi H. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. J Diabetes Investig. 2021 Jul;12(7):1293-1300. doi: 10.1111/jdi.13458. Epub 2020 Dec 13.
Reference Type
BACKGROUND
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1595-1622. doi: 10.1210/jc.2019-00221.
Reference Type
BACKGROUND
Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6.
Reference Type
BACKGROUND
Hiligsmann M, Reginster JY. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int. 2019 Mar;30(3):649-658. doi: 10.1007/s00198-018-04821-7. Epub 2019 Jan 30.
Reference Type
BACKGROUND
McClung MR, Ebetino FH. History of risedronate. Bone. 2020 Aug;137:115407. doi: 10.1016/j.bone.2020.115407. Epub 2020 May 6.
Reference Type
BACKGROUND
American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc. 2014 Jan;62(1):147-52. doi: 10.1111/jgs.12631. Epub 2013 Dec 18.
Reference Type
BACKGROUND
Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999 Aug;104(4):439-46. doi: 10.1172/JCI6610.
Reference Type
BACKGROUND
Balani DH, Ono N, Kronenberg HM. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest. 2017 Sep 1;127(9):3327-3338. doi: 10.1172/JCI91699. Epub 2017 Jul 31.
Reference Type
BACKGROUND
Brent MB, Stoltenborg FE, Bruel A, Thomsen JS. Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice. Front Endocrinol (Lausanne). 2021 Apr 19;12:628994. doi: 10.3389/fendo.2021.628994. eCollection 2021.
Reference Type
BACKGROUND
McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018 Jul;25(7):767-771. doi: 10.1097/GME.0000000000001080.
Reference Type
BACKGROUND
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904.
Reference Type
BACKGROUND
Haas AV, LeBoff MS. Osteoanabolic Agents for Osteoporosis. J Endocr Soc. 2018 Jul 9;2(8):922-932. doi: 10.1210/js.2018-00118. eCollection 2018 Aug 1.
Reference Type
BACKGROUND
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997 Aug 23;350(9077):550-5. doi: 10.1016/S0140-6736(97)02342-8.
Reference Type
BACKGROUND
Choi H, Magyar CE, Nervina JM, Tetradis S. Different duration of parathyroid hormone exposure distinctively regulates primary response genes Nurr1 and RANKL in osteoblasts. PLoS One. 2018 Dec 21;13(12):e0208514. doi: 10.1371/journal.pone.0208514. eCollection 2018.
Reference Type
BACKGROUND
Choudhary S, Santone E, Yee SP, Lorenzo J, Adams DJ, Goetjen A, McCarthy MB, Mazzocca AD, Pilbeam C. Continuous PTH in Male Mice Causes Bone Loss Because It Induces Serum Amyloid A. Endocrinology. 2018 Jul 1;159(7):2759-2776. doi: 10.1210/en.2018-00265.
Reference Type
BACKGROUND
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
118.2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
NCT00353080
COMPLETED
PHASE3
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
NCT00092014
COMPLETED
PHASE3
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
NCT00577421
COMPLETED
PHASE3
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
NCT01611571
COMPLETED
PHASE3
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
NCT00365456
COMPLETED
PHASE3
To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
NCT01904110
COMPLETED
PHASE4
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
NCT00221299
COMPLETED
PHASE4
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
NCT00358176
COMPLETED
PHASE3
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
NCT01249261
COMPLETED
PHASE3
Risedronate in Osteopenic Postmenopausal Women
NCT00345644
COMPLETED
PHASE3
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
NCT00092040
COMPLETED
PHASE3
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00541658
COMPLETED
PHASE3
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01709110
COMPLETED
PHASE4
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
NCT00577837
COMPLETED
PHASE2
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
NCT00790101
TERMINATED
PHASE4
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
NCT00426777
COMPLETED
PHASE3
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
NCT00577850
COMPLETED
PHASE1
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
NCT00054418
COMPLETED
PHASE3
Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
NCT00503399
COMPLETED
PHASE3
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
NCT05630768
COMPLETED
PHASE4
Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
NCT01675297
COMPLETED
PHASE4
A Study of Monthly Risedronate for Osteoporosis
NCT00247273
COMPLETED
PHASE3
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
NCT01575873
COMPLETED
PHASE3
36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
NCT02106442
COMPLETED
Vitamin K and Bone Turnover in Postmenopausal Women
NCT00062595
COMPLETED
PHASE3